This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
July 24, 2012 /PRNewswire/ --
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has completed the previously announced underwritten public offering of 33,000,000 shares of its common stock, offered at a price to the public of
$1.00 per share. In addition, the Company has sold 4,950,000 shares of its common stock at a price to the public of
$1.00 per share pursuant to the underwriters' option to purchase additional shares, resulting in a total public offering of 37,950,000 shares. The gross proceeds to the Company from the sale of shares in this offering, before deducting customary underwriting discounts and commissions, were
$37,950,000. Anthera intends to use the net proceeds from this offering for general corporate purposes.
Piper Jaffray & Co. and Leerink Swann LLC acted as joint book-running managers in the offering. Canaccord Genuity acted as lead manager in the offering. Summer Street Research Partners acted as co-manager in the offering.
The securities described above were offered by the Company pursuant to a shelf registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC"). A final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC's website at
http://www.sec.gov. Copies of the final prospectus supplement relating to these securities may be obtained from
Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at
email@example.com, or from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110 or by telephone at 800-808-7525 or by email at
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.